17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck

To receive upfront payment and royalties

Mumbai, July 10, 2009: Sun Pharmaceutical Industries Ltd. ("Sun Pharma", collectively with its 100% subsidiary) announced that along with Caraco Pharmaceutical Laboratories, Ltd ("Caraco"), it had entered into agreements with Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., and H. Lundbeck A/S (collectively, "Forest") to settle the legal proceedings related to Lexapro® (escitalopram oxalate) tablets.

Among other things, with respect to Sun Pharma and Caraco, the agreement contains the following provisions:

- 1. Sun Pharma will license to Lundbeck on a worldwide basis certain patent applications related to the synthesis of escitalopram and citalopram in exchange for an upfront payment and, if the technology is used, royalties on sales.
- 2. Forest will provide licenses to Caraco for any patents related to Lexapro® and with respect to the marketing of Caraco's generic version of the product as of the date that any third party generic that has received final approval from the FDA enters the market other than an authorized generic or the first filer with Hatch-Waxman related exclusivity.
- 3. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance against royalties and royalties on net sales of these products.
- 4. Forest will reimburse Caraco for a portion of their costs related to this litigation.

These agreements will be subject to review by the U.S. Federal Trade Commission.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota		Mira Desai	
Tel	+91 22 6645 5645, Xtn 605	Tel	+91 22 6645 5645, Xtn 606
Tel Direct	+91 22 66455605	Tel Direct	+91 22 66455606
Mobile	+91 98670 10529	Mobile	+91 98219 23797
E mail	uday.baldota@sunpharma.com	E mail	mira.desai@sunpharma.com